{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:02:16Z","timestamp":1791666136973,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The First Affiliated Hospital of Naval Medical University","award":["2021JCMS01"],"award-info":[{"award-number":["2021JCMS01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04958-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:24:43Z","timestamp":1778329483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy"],"prefix":"10.1186","volume":"27","author":[{"given":"Yulong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengnan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"1","key":"4958_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"HLB B G R B","year":"2009","unstructured":"B G R B HLB, G\u00e9rard L, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa0810457.","journal-title":"N Engl J Med"},{"issue":"2","key":"4958_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","volume":"95","author":"AS Bobart","year":"2019","unstructured":"Bobart AS, Vriese DSA, Pawar SA, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95(2):429\u201338. https:\/\/doi.org\/10.1016\/j.kint.2018.10.021.","journal-title":"Kidney Int"},{"issue":"2","key":"4958_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"S A V D","year":"2017","unstructured":"S A V D, J R G, A K N, et al. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrology: JASN 2017. 2017;28(2):421\u201330. https:\/\/doi.org\/10.1681\/ASN.2016070776.","journal-title":"J Am Soc Nephrology: JASN 2017"},{"issue":"8","key":"4958_CR4","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/J.EKIR.2025.04.059","volume":"10","author":"M Allinovi","year":"2025","unstructured":"Allinovi M, Teisseyre M, Accinno M, et al. Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy. Kidney Int Rep. 2025;10(8):2621\u20139. https:\/\/doi.org\/10.1016\/J.EKIR.2025.04.059.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"4958_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41581-019-0200-1","volume":"15","author":"N Aikaterini","year":"2019","unstructured":"Aikaterini N, Megan G. MENTOR heralds a new era of therapy for membranous nephropathy. Nat Rev Nephrol. 2019;15(11):664\u20136. https:\/\/doi.org\/10.1038\/s41581-019-0200-1.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"4958_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"N Maarten","year":"2009","unstructured":"Maarten N, J R D K, Minnie S. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrology: CJASN. 2009;4(2):481\u2013508. https:\/\/doi.org\/10.2215\/CJN.04800908.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"4958_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","volume":"97","author":"N Seyfizadeh","year":"2016","unstructured":"Seyfizadeh N, Seyfizadeh N, Hasenkamp J, et al. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol. 2016;97:275\u201390. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.09.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"4958_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza CF, Zand L. Successful Treatment of Patients with Refractory PLA 2 R-Associated Membranous Nephropathy with Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis. 2020;76(6):883\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.444.","journal-title":"Am J Kidney Dis"},{"issue":"01","key":"4958_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1006-298X.2025.01.001","volume":"34","author":"D Chen","year":"2025","unstructured":"Chen D, Tu Y, Li H, et al. Obinutuzumab in treatment of high risk or refractory phospholipase A2 receptor associated membranous nephropathy. Chin J Nephrol Dialysis Transplantation. 2025;34(01):1\u20137. https:\/\/doi.org\/10.3969\/j.issn.1006-298X.2025.01.001.","journal-title":"Chin J Nephrol Dialysis Transplantation"},{"issue":"Suppl 4","key":"4958_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIG0 2021 Clinical Practice Guideline for the Kidney Management of Glomerular Diseases. Kidney Int. 2021;100(Suppl 4):S1\u2013276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"issue":"1","key":"4958_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus Rituximab. Bri J Haematol. 2018;182(1):29\u201345. https:\/\/doi.org\/10.1111\/bjh.15232.","journal-title":"Bri J Haematol"},{"issue":"7","key":"4958_CR12","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1002\/MCO2.614","volume":"5","author":"M Wang","year":"2024","unstructured":"Wang M, Yang J, Fang X, et al. Membranous nephropathy: pathogenesis and treatments. MedComm. 2024;5(7):e614. https:\/\/doi.org\/10.1002\/MCO2.614.","journal-title":"MedComm"},{"key":"4958_CR13","doi-asserted-by":"publisher","first-page":"599974","DOI":"10.3389\/FIMMU.2020.599974","volume":"11","author":"EJJ K","year":"2021","unstructured":"K EJJ, F. M E V GHR, et al. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys. Front Immunol. 2021;11:599974\u2013599974. https:\/\/doi.org\/10.3389\/FIMMU.2020.599974.","journal-title":"Front Immunol"},{"issue":"12","key":"4958_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrneph.2011.149","volume":"7","author":"L Youhua","year":"2011","unstructured":"Youhua L. Cellular and molecular mechanisms of kidney fibrosis. Nat Rev Nephrol. 2011;7(12):684\u201396. https:\/\/doi.org\/10.1038\/nrneph.2011.149.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4958_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12079-017-0382-x","volume":"11","author":"Z Fengge","year":"2017","unstructured":"Fengge Z, Xueyuan B, Xiangmei C. B lymphocytes in renal interstitial fibrosis. J cell communication Signal. 2017;11(3):213\u20138. https:\/\/doi.org\/10.1007\/s12079-017-0382-x.","journal-title":"J cell communication Signal"},{"key":"4958_CR16","doi-asserted-by":"publisher","unstructured":"Hui H, Jinzhou Z, Yaqiong W, et al. Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction. J Pathol. 241(1):80\u201390. https:\/\/doi.org\/10.1002\/path.4831.","DOI":"10.1002\/path.4831"},{"issue":"2","key":"4958_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10059-009-0114-z","volume":"28","author":"K Kazue","year":"2009","unstructured":"Kazue K, Hirofumi S, Yumi Y, et al. Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4(+) T cells. Mol Cells. 2009;28(2):125\u201330. https:\/\/doi.org\/10.1007\/s10059-009-0114-z.","journal-title":"Mol Cells"},{"issue":"9","key":"4958_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","volume":"41","author":"T Illidge","year":"2015","unstructured":"Illidge T, Klein C, Sehn HL, et al. Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treat Rev. 2015;41(9):784\u201392. https:\/\/doi.org\/10.1016\/j.ctrv.2015.07.003.","journal-title":"Cancer Treat Rev"},{"key":"4958_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS-2021-220920","author":"ARF Gustavo","year":"2023","unstructured":"Gustavo ARF, D M C A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2021-220920.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4958_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/S40265-023-01855-Y","volume":"83","author":"D Le","year":"2023","unstructured":"Le D, Gaosi X. Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy. Drugs. 2023;83(6):507\u201330. https:\/\/doi.org\/10.1007\/S40265-023-01855-Y.","journal-title":"Drugs"},{"issue":"3","key":"4958_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/J.EKIR.2024.12.012","volume":"10","author":"M Teisseyre","year":"2025","unstructured":"Teisseyre M, Allinovi M, Audard V, et al. Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies. Kidney Int Rep. 2025;10(3):753\u201361. https:\/\/doi.org\/10.1016\/J.EKIR.2024.12.012.","journal-title":"Kidney Int Rep"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04958-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:00:27Z","timestamp":1779282027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04958-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4958"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04958-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of the First Affiliated Hospital of Naval Medical University(Shanghai Changhai Hospital)(approval number CHEC2021-181). All experiments were conducted in accordance with relevant guidelines and regulations. The requirement for informed consent was waived by the Research Ethics Committee of the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital). We hereby confirm that this study complies with the Declaration of Helsinki. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}